Alpa Laboratories Declares Q2 FY27 Results: Standalone Net Loss ₹187 Crore, Consolidated Net Loss ₹184 Crore
Alpa Laboratories reported its Q2 FY27 results. Standalone net loss was ₹187.01 lakh and consolidated net loss was ₹184.54 lakh for the quarter ended September 30, 2026. Revenue from operations stood at ₹3,097.56 lakh on a standalone basis.
The announcement of substantial net losses for the quarter is a material event that is likely to significantly impact investor sentiment and the company's stock price.
The company reported significant net losses on both standalone and consolidated bases for the quarter ended September 30, 2026, indicating a negative financial performance.
Alpa Laboratories Limited announced the outcome of its Board Meeting held on November 14, 2026. The board approved the Un-Audited Standalone & Consolidated Financial Results for the Quarter and half-year ended September 30, 2026, along with the Limited Review Report from the Statutory Auditor.
For the quarter ended September 30, 2026, the company reported a standalone net loss of ₹187.01 lakh (₹1.87 crore) compared to a profit of ₹103.84 lakh in the same quarter last year. Revenue from operations for the standalone entity stood at ₹3,097.56 lakh (₹30.98 crore), a slight increase from ₹2,563.21 lakh in the previous year's quarter. Expenses were higher, particularly the cost of materials consumed and other expenses, leading to the net loss.
On a consolidated basis, the company reported a net loss of ₹184.54 lakh (₹1.85 crore) for the quarter ended September 30, 2026. Consolidated revenue from operations was ₹3,097.56 lakh (₹30.98 crore). The consolidated results also reflect increased expenses contributing to the loss.
The half-year ended September 30, 2026, saw a standalone net loss of ₹83.17 lakh (₹0.83 crore) and consolidated net loss of ₹87.30 lakh (₹0.87 crore). The company's financial performance indicates a challenging period with significant losses reported in the current quarter.
What to do with a filing like this
Alpa Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alpa Laboratories Limited. Read the original for the full detail.